Stagflation Risks: Why the 2022 Landscape is Different
Loading...

Higher Input Costs

Corporate profit growth is at risk from rising producer prices and accelerating compensation costs.

Many companies in the goods producing sector are likely to see profit growth erode with higher input costs, even if some sectors, such as energy, may do well.   

Producer price inflation has surged to the 20% territory, growing more than twice as fast as consumer price inflation.  If you are watching corporate profits, monitoring developments in producer prices may be much more important than overall inflation.

Producer Price Inflation

And the labor market is tight, too.  The U.S. is seeing rising compensation costs for all employees, not just hourly workers.  Total compensation costs are still growing less than consumer price inflation; however, many analysts expect labor cost pressures to only accelerate in this environment.

The conclusion is that the share of corporate profits in nominal GDP is likely to decline from the current elevated level.  It is an open question as to whether equity markets have fully discounted both eroding profits and a rising hurdle rate (that is, bond yields), but slowing industrial production could be a drag on real GDP growth.

Corporate Profits

The bottom line is that rising inflation, withdrawal of policy stimulus, and potential for eroding corporate profit margins all add to the risks of stagflation – that is, high inflation with little economic growth. The stagflation potential puts tremendous pressure on the Federal Reserve.  No one wants a recession, and no one wants long-term, persistent inflation.  Can the Fed negotiate a soft-landing for the economy in the face of these powerful risks? Only time will tell, but the probabilities of the U.S. economy settling into an extended period of stagflation have risen materially.

Loading...

 

 

OpenMarkets is an online magazine and blog focused on global markets and economic trends. It combines feature articles, news briefs and videos with contributions from leaders in business, finance and economics in an interactive forum designed to foster conversation around the issues and ideas shaping our industry.

All examples are hypothetical interpretations of situations and are used for explanation purposes only. The views expressed in OpenMarkets articles reflect solely those of their respective authors and not necessarily those of CME Group or its affiliated institutions. OpenMarkets and the information herein should not be considered investment advice or the results of actual market experience. Neither futures trading nor swaps trading are suitable for all investors, and each involves the risk of loss. Swaps trading should only be undertaken by investors who are Eligible Contract Participants (ECPs) within the meaning of Section 1a(18) of the Commodity Exchange Act. Futures and swaps each are leveraged investments and, because only a percentage of a contract’s value is required to trade, it is possible to lose more than the amount of money deposited for either a futures or swaps position. Therefore, traders should only use funds that they can afford to lose without affecting their lifestyles and only a portion of those funds should be devoted to any one trade because traders cannot expect to profit on every trade. BrokerTec Americas LLC (“BAL”) is a registered broker-dealer with the U.S. Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (www.FINRA.org), and is a member of the Securities Investor Protection Corporation (www.SIPC.org). BAL does not provide services to private or retail customers.. In the United Kingdom, BrokerTec Europe Limited is authorised and regulated by the Financial Conduct Authority. CME Amsterdam B.V. is regulated in the Netherlands by the Dutch Authority for the Financial Markets (AFM) (www.AFM.nl). CME Investment Firm B.V. is also incorporated in the Netherlands and regulated by the Dutch Authority for the Financial Markets (AFM), as well as the Central Bank of the Netherlands (DNB).

©2025 CME Group Inc. All rights reserved